Cocrystal Pharma Inc - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
COCP Nasdaq 2834 https://www.cocrystalpharma.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Cocrystal Pharma Inc

Cocrystal Pharma to Present at the H.C. Wainwright Global Investment Conference - May 18th, 2022 12:00 pm
COCP: Cocrystal Pharma Releases 2022 1st Quarter Results and Provides an Update on the Current Pipeline Programs - May 12th, 2022 12:12 pm
Cocrystal Pharma Reports First Quarter 2022 Financial Results and Provides Updates on its Antiviral Development Programs and Milestones - May 11th, 2022 12:00 pm
Cocrystal Pharma Collaborates with the National Institute of Allergy and Infectious Diseases to Evaluate COVID-19 Protease Inhibitors - Apr 21st, 2022 12:00 pm
Cocrystal Pharma to Present at the Life Science Innovation Northwest 2022 Conference - Apr 19th, 2022 12:00 pm
Cocrystal Pharma to Present at the Noble Capital Markets’ NobleCon18 Conference - Apr 14th, 2022 12:00 pm
Cocrystal Pharma Posts Favorable Preliminary Data From Influenza A Antiviral Candidate Trial - Apr 12th, 2022 3:01 pm
Cocrystal Pharma Reports Favorable Preliminary Data from Phase 1 Initial Cohorts with CC-42344, a Novel, Broad-Spectrum Influenza A antiviral - Apr 12th, 2022 12:00 pm
10 Biotech Penny Stocks with Growth Catalysts - Apr 6th, 2022 2:15 pm
We're Hopeful That Cocrystal Pharma (NASDAQ:COCP) Will Use Its Cash Wisely - Mar 30th, 2022 6:57 pm
COCP: Cocrystal Pharma releases 2021 fiscal year results and provides an update on the current pipeline programs - Mar 25th, 2022 11:30 am
Cocrystal Pharma Reports 2021 Financial Results and Provides Updates on Development Programs and Milestones - Mar 23rd, 2022 8:05 pm
Cocrystal Pharma to Participate in the Maxim Group 2022 Virtual Growth Conference - Mar 22nd, 2022 12:00 pm
Cocrystal Pharma Initiates Enrollment in Phase 1 Influenza A Study with Novel, Broad-Spectrum, Orally Administrated Antiviral CC-42344 - Mar 10th, 2022 1:00 pm
Cocrystal Pharma to Participate in Upcoming Investment Conferences - Mar 3rd, 2022 1:00 pm
COCP: Cocrystal Pharma has secured funding to enter three clinical trials and fund planned operations through 2023 - Feb 24th, 2022 1:10 pm
Cocrystal Pharma To Develop Additional Two Antiviral Drug Candidates For COVID-19 - Jan 27th, 2022 5:22 pm
Cocrystal Pharma Selects Two Lead Antiviral Drug Candidates for its COVID-19 Oral Drug Program - Jan 27th, 2022 1:00 pm
SomaLogic Announces Preliminary Revenue for Full Year 2021 Above Guidance Range - Jan 11th, 2022 12:00 pm
SomaLogic Announces Appointment of Adam Taich as Chief Business Officer - Jan 10th, 2022 9:10 pm